UROONCO BCa chief editor Dr. Benjamin Pradere talk to Prof. Thomas Powles and Prof. Shahrokh Shariat on the strategies for perioperative muscle-invasive bladder cancer (MIBC).
They discuss the evolving management of muscle-invasive bladder cancer, focusing on perioperative treatments and groundbreaking trial results. They also highlight the shift from traditional approaches to perioperative immunotherapy, including promising outcomes from EV + pembrolizumab, with improved response rates and survival. And they debate the future role of radical cystectomy, the need for reliable biomarkers like ctDNA, and the importance of ongoing trials to guide treatment de-escalation and personalised care.